Cytomel (Liothyronine) and PPIs (Omeprazole, Pantoprazole): Interaction Guide

What Is the Interaction Between Liothyronine and PPIs?

The core concern is straightforward. Proton pump inhibitors suppress gastric acid secretion by irreversibly blocking the H+/K+-ATPase pump on parietal cells, raising intragastric pH from a fasting value near 1-2 to values above 4 and sometimes above 6 during sustained therapy. Liothyronine, as a synthetic triiodothyronine salt, requires an adequately acidic gastric environment for optimal dissolution and absorption through the proximal small intestine. When that environment is made more alkaline, the rate and possibly the extent of T3 uptake may fall.

This is not a metabolic drug-drug interaction. Neither omeprazole nor pantoprazole meaningfully inhibit the cytochrome P450 enzymes (primarily CYP1A2 and CYP2C19 are involved in PPI biotransformation) in a way that changes liothyronine plasma half-life. The mechanism is entirely absorption-based, which means the interaction is most relevant at the moment of ingestion rather than during distribution or elimination.

How PPIs Change Gastric pH

Standard omeprazole 20 mg once daily raises mean 24-hour intragastric pH from approximately 1.5 to roughly 4.0 in healthy volunteers, per pharmacokinetic data cited in the omeprazole prescribing information [1]. Pantoprazole 40 mg achieves a similar pH profile, with median 24-hour pH values of 3.8 to 4.5 in clinical studies [2]. Both drugs reach near-maximal acid suppression within 4-5 days of daily dosing.

At pH above 5, many weakly acidic drugs show reduced dissolution from tablet or capsule form. Liothyronine sodium is administered as a small-dose solid tablet (typically 5 mcg to 50 mcg). The amount of drug is tiny, so even modest changes in dissolution kinetics could in theory shift the fraction absorbed.

What Pharmacokinetic Data Say About T3 Absorption

The FDA-approved Cytomel (liothyronine sodium) prescribing information states that oral T3 is "95 percent absorbed from the gastrointestinal tract" under standard conditions [3]. Bioavailability studies have been done primarily in euthyroid and hypothyroid subjects without concomitant acid suppressants, leaving a direct head-to-head pharmacokinetic trial specifically for liothyronine plus PPI absent from the published literature as of early 2025.

The parallel evidence base comes from the more extensively studied levothyroxine (T4), which shares the same proximal small-intestinal absorption site. A 2006 study by Centanni et al. Published in the New England Journal of Medicine (N=48 hypothyroid patients) demonstrated that omeprazole co-administration reduced levothyroxine bioavailability, requiring a mean dose increase of approximately 22 mcg per day to maintain stable TSH [4]. Because T3 and T4 share the same intestinal transporter-mediated uptake pathway, this finding is mechanistically applicable to liothyronine, though the magnitude may differ given T3's higher passive permeability.

Mechanism in Detail: Why Gastric pH Affects T3 Uptake

Ionization State and Dissolution

Liothyronine sodium dissociates in aqueous solution. At low gastric pH, the compound exists in a form conducive to rapid dissolution from the tablet matrix. As pH climbs, the equilibrium shifts. The practical implication is that gastric residence time combined with altered ionization may reduce the concentration gradient driving absorption across the duodenal mucosa.

Transporter-Mediated Intestinal Uptake

Once dissolved, T3 crosses the intestinal epithelium partly via organic anion transporting polypeptides (OATPs) and monocarboxylate transporter 8 (MCT8). These transporters are not inhibited by omeprazole or pantoprazole at clinical concentrations. The PPI effect is therefore entirely upstream, at the dissolution stage, not at the transporter level. This distinction matters clinically: spacing the doses reduces the interaction because the PPI is most pharmacologically active in the immediate post-dose window.

Time Course of pH Suppression

Omeprazole taken 30 minutes before breakfast produces peak acid suppression during the post-prandial period rather than in the fasting state. If liothyronine is taken on an empty stomach 30-60 minutes before the PPI and before breakfast, the two drugs occupy gastric space at different times, partially sidestepping the pH-mediated absorption barrier. This is the standard counseling approach recommended by endocrinology practice groups [5].

How Severe Is This Interaction?

The interaction is classified as minor to moderate by major clinical pharmacology databases. It does not appear on the FDA's list of contraindicated drug combinations, and neither the Cytomel prescribing information nor the omeprazole or pantoprazole labels carry a boxed warning or formal contraindication related to this pairing [1, 2, 3].

Risk Stratification by Patient Profile

Not every patient taking both drugs will notice clinical consequences. The table below outlines which patients face the highest risk of subclinical or overt hypothyroidism from this combination.

| Patient Profile | Risk Level | Rationale | |---|---|---| | Stable T3 replacement, normal TSH, standard doses | Low | Modest absorption shift likely compensated by residual absorption capacity | | Near-lower-limit TSH, borderline free T3 | Moderate | Little buffer; even a 10-15% absorption drop may push TSH above range | | Elderly patients with baseline achlorhydria | Moderate-High | Additive pH elevation on a stomach already less acidic | | Malabsorption syndromes (celiac, short bowel) | High | Pre-existing reduced absorption amplified by PPI effect | | High-dose T3 for thyroid cancer suppression | Moderate | Tight TSH targets leave no room for variability |

Evidence Extrapolated From Levothyroxine Studies

Because no large randomized trial has examined liothyronine plus PPI specifically, the best available evidence is extrapolated from T4 data. Beyond the Centanni et al. NEJM study, a retrospective cohort published in Thyroid (2017, N=313 hypothyroid outpatients on stable levothyroxine) found that initiation of a PPI was associated with a mean TSH increase of 0.8 mIU/L at 12 weeks, with 18% of patients ultimately requiring a levothyroxine dose increase [6]. Extrapolating to liothyronine is biologically reasonable but not proven in a controlled trial.

Clinical Management: What to Do When a Patient Needs Both Drugs

Step 1: Optimize Timing Before Changing the Dose

The simplest and most effective first intervention is timing separation. Patients should take liothyronine on an empty stomach, 30-60 minutes before the PPI dose and 30-60 minutes before breakfast. This is consistent with the general thyroid hormone administration guidance in the American Thyroid Association's 2014 hypothyroidism management guidelines, which state: "Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast or before the evening meal, to maximize absorption" [5]. The same principle applies to liothyronine given their shared absorption site.

Step 2: Recheck TSH and Free T3

Obtain baseline TSH and free T3 before adding the PPI, then repeat at 6-8 weeks. This is the same recheck interval used after any liothyronine dose change, reflecting the time needed for TSH to reach a new steady state after a shift in thyroid hormone levels. If TSH has risen by more than 0.5 mIU/L above the patient's established baseline and is now outside the target range, a dose adjustment may be warranted.

Step 3: Consider Whether the PPI Is Actually Necessary

Many patients are on PPIs for indications that could be managed with H2 receptor antagonists (famotidine, cimetidine) or even dietary modification. H2 blockers produce less profound and shorter-duration acid suppression than PPIs. A 2020 review in the American Journal of Gastroenterology noted that H2 blockers raise 24-hour intragastric pH to approximately 2.0-3.0, compared with 4.0-5.0 for PPIs, potentially producing a smaller absorption effect on co-administered drugs [7]. Famotidine in particular lacks significant CYP2C19 activity and carries a cleaner interaction profile. Discussing the appropriateness of PPI therapy with the prescribing gastroenterologist or primary care provider is worthwhile in any patient with difficult-to-control thyroid hormone levels.

Step 4: Dose Adjustment If Needed

If TSH rises despite optimized timing, a modest liothyronine dose increase of 5 mcg per day is a reasonable first step. Many clinicians use the same proportional adjustment applied to levothyroxine (roughly 10-25% increase), though this is extrapolated practice rather than a T3-specific guideline recommendation. Doses should be adjusted no more frequently than every 6-8 weeks to allow adequate assessment.

Comparing Omeprazole vs. Pantoprazole vs. Other PPIs

All PPIs share the same mechanism but differ in pharmacokinetics and CYP2C19 metabolic liability. From a thyroid hormone absorption standpoint, the degree of gastric pH suppression is the relevant variable, and all standard-dose PPIs produce broadly comparable pH elevation during the first few hours after dosing.

Omeprazole (Prilosec, 20-40 mg)

Omeprazole is a potent CYP2C19 inhibitor, which is relevant for drugs metabolized by that enzyme but not for liothyronine itself. Its acid-suppressive effect is well characterized [1]. Immediate-release omeprazole reaches peak plasma concentration in 30-90 minutes; acid suppression peaks at 1-2 hours post-dose.

Pantoprazole (Protonix, 40 mg)

Pantoprazole has a lower CYP2C19 inhibitory potential compared with omeprazole. Its acid-suppressive profile is similar in magnitude, though some pharmacokinetic data suggest slightly shorter duration of effect with standard 40 mg dosing compared with esomeprazole 40 mg [2]. From a practical standpoint, the thyroid hormone absorption interaction is similar across pantoprazole and omeprazole.

Esomeprazole and Lansoprazole

Esomeprazole 40 mg produces the highest degree of sustained acid suppression among commonly used PPIs. Lansoprazole 30 mg produces a pH profile similar to omeprazole 20 mg. Neither has been studied specifically with liothyronine, but the same precautions apply.

Patient Counseling Points

Direct, clear patient education reduces the risk that this interaction will produce undetected hypothyroid drift. Key messages to communicate:

1. Take liothyronine first thing in the morning on an empty stomach, at least 30-60 minutes before taking the PPI and before eating.
2. Do not take liothyronine within 4 hours of antacids, calcium supplements, iron tablets, or magnesium-containing preparations, as these compounds independently impair thyroid hormone absorption.
3. Symptoms of undertreated hypothyroidism, including fatigue, cold intolerance, constipation, weight gain, and brain fog, should prompt a TSH check rather than self-adjustment.
4. Inform every prescriber including gastroenterologists, primary care providers, and pharmacists about all thyroid medications being taken.
5. Do not stop the PPI abruptly without discussing it with the prescribing clinician; rebound acid hypersecretion can occur after prolonged PPI use.

The American Association of Clinical Endocrinology (AACE) practice guidelines note that "multiple medications and supplements are known to interfere with thyroid hormone absorption and should be administered separated by at least 4 hours" from thyroid hormone doses [8]. While the AACE statement specifically enumerates calcium carbonate, ferrous sulfate, and aluminum-containing antacids rather than PPIs by name, the underlying principle of absorption spacing is the same.

Other Liothyronine Drug Interactions to Know

PPIs are not the only class of drugs that affect liothyronine levels. Clinicians managing patients on Cytomel should screen for the following concurrent therapies at every visit.

Drugs That Reduce T3 Absorption

• Calcium carbonate and calcium citrate: Reduce levothyroxine and liothyronine absorption when taken simultaneously; separate by at least 4 hours.
• Ferrous sulfate (iron supplements): A prospective study by Shakir et al. Showed a 37% reduction in levothyroxine bioavailability with co-administered iron [9]; the same applies to T3.
• Aluminum- and magnesium-containing antacids: Bind thyroid hormone in the gut lumen.
• Cholestyramine and colestipol: Bile acid sequestrants bind T3 in the intestine and significantly reduce absorption; separate by at least 4-6 hours.
• Sucralfate: Raises local gastric pH and may bind T3 directly.

Drugs That Accelerate T3 Clearance

• Rifampin: Induces CYP enzymes involved in T3 conjugation and clearance; patients may need higher liothyronine doses.
• Carbamazepine and phenytoin: Hepatic enzyme inducers; reduce circulating thyroid hormone concentrations.
• Sertraline: Case reports and small studies document decreased thyroid hormone levels in hypothyroid patients starting sertraline; mechanism is unclear but possibly involves altered T3 distribution or clearance.

Pharmacodynamic Interactions

• Warfarin: Thyroid hormones increase the catabolism of vitamin K-dependent clotting factors; starting or increasing liothyronine may potentiate anticoagulation and require INR monitoring and warfarin dose reduction.
• Sympathomimetics (epinephrine, pseudoephedrine): Thyroid hormone sensitizes the heart to catecholamines; combined use in patients with cardiovascular disease warrants caution.
• Beta-blockers (propranolol, atenolol): Propranolol at high doses (greater than 160 mg/day) inhibits the peripheral conversion of T4 to T3, relevant in patients on combination T4/T3 therapy.
• Digoxin: Hypothyroid patients have reduced volume of distribution for digoxin; correcting hypothyroidism with liothyronine may lower digoxin levels and require dose adjustment.

Monitoring Protocol Summary

The following testing schedule is appropriate for any patient starting a PPI while on a stable liothyronine regimen.

| Timepoint | Test | Action Threshold | |---|---|---| | Baseline (before starting PPI) | TSH, free T3 | Establish individual reference | | 6-8 weeks after PPI initiation | TSH, free T3 | TSH rise >0.5 mIU/L above baseline: reassess timing, consider dose adjustment | | 12 weeks if dose was adjusted | TSH, free T3 | Confirm TSH within target range | | Annually thereafter | TSH | Routine thyroid monitoring | | Any time new hypothyroid symptoms appear | TSH, free T3 | Do not wait for the annual check |

If TSH remains stable at 6-8 weeks with optimized timing, no dose change is needed and annual monitoring is sufficient.

Special Populations

Elderly Patients

Aging is associated with reduced gastric acid secretion (atrophic gastritis), a condition that independently impairs thyroid hormone absorption. Adding a PPI to an already hypochlorhydric stomach may produce a more pronounced absorption reduction than seen in younger adults. Older patients should have TSH checked within 6 weeks of PPI initiation rather than waiting 8 weeks.

Patients With Celiac Disease or Short Bowel Syndrome

Intestinal malabsorption syndromes require higher baseline liothyronine doses in many patients. PPI-related pH changes compound the absorption problem. Liquid formulations of levothyroxine have been shown to bypass some absorption deficits in these populations, and a similar strategy might be explored for T3 supplementation after discussion with an endocrinologist, though a liquid liothyronine preparation is not commercially available in the United States as of early 2025.

Pregnancy

Thyroid hormone requirements increase by 25-50% in the first trimester and remain elevated through delivery. Pregnant patients on liothyronine who require PPI therapy for gestational reflux should have TSH checked every 4 weeks through mid-pregnancy and at least once per trimester thereafter, consistent with the American Thyroid Association's 2017 thyroid disease in pregnancy guidelines [10].